Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

NCT05956041 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Cutaneous T Cell Lymphoma
Fungoides Mycosis Sezary Syndrome

Interventions

DRUG: Pembrolizumab
DRUG: Mogamulizumab

Sponsor

University of Michigan Rogel Cancer Center

Collaborators

[object Object]
[object Object]